Insmed (NASDAQ:INSM) CFO Sells $116,942.32 in Stock

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein sold 748 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at approximately $12,469,365.72. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Thursday, January 8th, Sara Bonstein sold 1,447 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $252,023.99.
• On Wednesday, January 7th, Sara Bonstein sold 1,678 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $293,767.46.
• On Tuesday, January 6th, Sara Bonstein sold 1,517 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $262,941.61.

Insmed Trading Down 0.8%

INSM opened at $149.86 on Friday. The stock has a market capitalization of $31.96 billion, a P/E ratio of -24.21 and a beta of 1.11. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The firm’s fifty day simple moving average is $174.90 and its 200 day simple moving average is $159.93.

Hedge Funds Weigh In On Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in INSM. EverSource Wealth Advisors LLC raised its position in Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares in the last quarter. Legato Capital Management LLC increased its stake in shares of Insmed by 14.9% during the 4th quarter. Legato Capital Management LLC now owns 40,006 shares of the biopharmaceutical company’s stock worth $6,963,000 after purchasing an additional 5,174 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Insmed by 107.7% during the 4th quarter. Global Retirement Partners LLC now owns 3,838 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,990 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Insmed in the 4th quarter valued at about $522,000. Finally, Pinkerton Wealth LLC acquired a new stake in Insmed in the 4th quarter valued at about $896,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on INSM shares. TD Cowen set a $241.00 target price on Insmed in a research report on Thursday, December 18th. Rothschild & Co Redburn set a $263.00 price target on shares of Insmed in a research note on Thursday, December 4th. Wedbush set a $203.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Mizuho set a $212.00 price target on shares of Insmed in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $203.45.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.